durch die börsenwelt. deine sichtweise beschränkt sich nur auf caly. hier sind die von mir angepriesenen zahlen von trinity oder trinity-müll wie du sagst. wie alt bist du eigentlich? darfst du überhaupt schon selbständig an den PC?
WENN IHR MAL GUT ZAHLEN SEHEN WOLLT,DANN HIER:
Trinity Biotech Announces Quarter 2 Results
DUBLIN, Ireland, Jul 28, 2004 /PRNewswire-FirstCall via COMTEX/ -- Trinity Biotech plc (NASDAQ: TRIB) today announced results for the quarter ended June 30, 2004.
Revenues in the quarter increased 22.6% to US$20.1 million compared to US$16.4 million in Quarter 1.
Compared to the same period last year revenues have increased by 19.8%.
Gross profit amounted to US$10.3 million, representing a gross margin of 51.4%. This compares to a gross profit of US$8.0 million in Quarter 1 and a gross margin of 48.9%.
R&D expenses have remained constant at US$1.2 million which represents 6.0% of revenues. SG&A expenses increased to US$7.1 million as compared to US$5.7 million in Quarter 1. This increase in SG&A costs is largely attributable to the addition of the salesforces of both Adaltis and Fitzgerald which were acquired during the quarter.
The net effect of the above factors was a profit before tax of US$1.2 million for the quarter and an EPS of 2.2 US cents.
Commenting on the results, Rory Nealon, Chief Financial Officer, said "Our revenue for the quarter has increased 23% over the previous quarter with 12% being attributable to our recent acquisitions and the remainder attributable to organic growth within the business. We are particularly pleased with the performance of our US and international salesforces which have delivered this 11% organic growth. Our gross margin has increased to 51.4% largely due to an increase in direct sales in the USA."
|
Thread abonnieren
genau @brokers. 